Amyloidosis is a disorder that represents different types of diseases in which an abnormal protein called amyloid is deposited. Amyloid can attach to and get deposited in various organs, tissues, and nerves, as well as other parts of the body. This deposition can affect the normal function of the respective organ or tissue. As the deposition of amyloid protein increases, health problems and organ damage can occur.
There is a shortage of approved medications for the treatment of amyloidosis. Hence, the unmet need is high, which is an opportunity for the development of novel therapies. Several organizations and pharmaceutical companies have collaborated to study to improve treatment options for autoimmune and inflammatory diseases, including amyloidosis. Strategic alliances that are formed through collaborations and license agreements are expected to help co-develop and commercialize drugs used for the symptomatic treatment of amyloidosis.
Request for: Free Sample Report
For instance, in September 2019, Alexion Pharmaceuticals Inc. (Alexion) announced a license agreement with BridgeBio Inc (BridgeBio). According to the terms of the agreement, Alexion will obtain an exclusive license from BridgeBio to develop and commercialize an investigational, orally administered small molecule called AG10 to treat amyloidosis in Japan. Hence, the strategic alliances is expected to be a major trend in the global amyloidosis therapeutics market to grow at a CAGR of 7.50% during the forecast period.